Managing hyponatraemia in patients with heart failure
Hyponatraemia has been associated with poor outcomes in patients with heart failure (HF).1 Tolvaptan is an oral, selective V2 receptor antagonist, indicated for the treatment of clinically significant hypervolaemic or euvolaemic hyponatraemia (associated with HF or syndrome of inappropriate antidiuretic hormone secretion [SIADH]) with either a serum Na+ concentration <125 mmol/L or less marked hyponatraemia that is symptomatic and resistant to fluid restriction.2 Trials have demonstrated the efficacy of tolvaptan for augmenting diuresis when administered with furosemide for management of congestive HF.2,3 The following case studies illustrate the use of tolvaptan in this setting.
